CardioVascular BioTherapeutics Inc. Hires Schwartz Communications for Corporate and Product Communications; Leading PR Firm Selected to Build Awareness of Novel Therapy for Cardiovascular Disease.

LAS VEGAS -- CardioVascular BioTherapeutics Inc. (OTCBB:CVBT) today announced that it has engaged Schwartz Communications Inc. (Waltham, Mass., and San Francisco, www.schwartz-pr.com), a premier public relations agency for innovative health care companies, as its agency-of-record. Schwartz has helped build prominence for significant medical advances in the medical device, biopharmaceutical and high technology sectors.

CardioVascular BioTherapeutics is a leading developer of therapies that address the many forms of cardiovascular disease by increasing the blood supply to ischemic areas, organs and tissues of the body. Its Cardio Vascu-Grow(TM), a protein member of the fibroblast growth factor family, stimulates the growth and production of new blood vessels, a process called angiogenesis. Clinical trials conducted in Germany in no-option heart patients indicate that once blood perfusion is established in the affected areas with injection of the same protein as Cardio Vascu-Grow(TM), those patients experienced a decrease in their chief clinical symptom, chest pain, and an increased ability to exercise for increased times. Such clinical improvements will hopefully translate into an increased life expectancy and better quality of life for those patients. Preliminary results from the U.S. Phase I Clinical trial were reported at the annual meeting of the Regenerative Medicine Organization in February 2006 by clinical investigators participating in the trial and indicated a similar decrease in chest pain symptoms in U.S. patients injected with Cardio Vascu-Grow(TM).

"We selected Schwartz Communications because of its excellent track record of success in building media awareness of medical advances and technologies through thoughtful educational campaigns designed at both patient and physician audiences," said Daniel C. Montano, president and CEO of CardioVascular BioTherapeutics. "Cardio Vascu-Grow has potential applications for the tens of millions of patients suffering from some form of cardiovascular disease in the U.S., and we recently completed the enrollment and treatment of all patients in our Phase I clinical trial carried out in patients with severe coronary artery disease, where no unexpected significant adverse events have been seen to date. In addition, we have initiated proof of concept clinical studies in patients suffering from chronic back pain. Schwartz has repeatedly shown its ability to build awareness of novel medical technologies, and we are excited to be working with them."

"CardioVascular BioTherapeutics is developing products which have the potential of impacting millions of people struggling with debilitating and deadly conditions and that's an important story to share," said Nigel Smith, senior vice president, Schwartz Communications. "We look forward to a long and productive relationship with CardioVascular BioTherapeutics."

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in the area of coronary artery disease in no-option heart patients, and one in the area of impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the United States. A foreign clinical trial relating to chronic back pain believed to be caused by impaired or blocked arteries has also been initiated.

About Schwartz Communications

Schwartz Communications was founded in 1990 by the husband and wife team of Steve and Paula Mae Schwartz. The agency currently has approximately 200 employees in its Waltham, Mass., and San Francisco offices. Schwartz Communications has garnered many honors, including having been three times on the Inc. 500 list of the fastest-growing private companies. Schwartz Communications is the largest PR agency headquartered in New England.

Cardio Vascu-Grow is a trademark of CardioVascular BioTherapeutics Inc.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.